M&A Deal Summary

Bausch Health Acquires Synergy Pharmaceuticals - Certain Assets

On February 26, 2019, Bausch Health acquired life science company Synergy Pharmaceuticals - Certain Assets from Synergy Pharmaceuticals for 195M USD

Acquisition Highlights
  • This is Bausch Health’s 20th transaction in the Life Science sector.
  • This is Bausch Health’s 19th largest (disclosed) transaction.
  • This is Bausch Health’s 21st transaction in the United States.
  • This is Bausch Health’s 3rd transaction in New York.

M&A Deal Summary
Date 2019-02-26
Target Synergy Pharmaceuticals - Certain Assets
Sector Life Science
Buyer(s) Bausch Health
Sellers(s) Synergy Pharmaceuticals
Deal Type Divestiture
Deal Value 195M USD

Target

Synergy Pharmaceuticals - Certain Assets

New York, New York, United States
Synergy Pharmaceuticals, Inc. - Certain Assets includes TRULANCE (plecanatide), a once-daily tablet approved for adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), and its investigational compound, dolcanatide, is an incremental peptide with established proof-of-concept studies in multiple GI conditions.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bausch Health

Laval, Quebec, Canada
Category Company
Sector Life Science
Employees20,270
Revenue 8.8B USD (2023)
DESCRIPTION

Bausch Health is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics. Bausch Health is based in Laval, Quebec.

DEAL STATS #
Overall 34 of 35
Sector (Life Science) 20 of 21
Type (Divestiture) 8 of 9
State (New York) 3 of 3
Country (United States) 21 of 22
Year (2019) 1 of 1
Size (of disclosed) 19 of 27
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-11-10 Obagi

Long Beach, California, United States

Obagi is a physician-dispensed brand in the dermo-cosmetic space, the highest-growth category in skin care. Obagi's product portfolio includes brands Obagi Nu-Derm®, Condition & Enhance®, Obagi-C® Rx, ELASTIDerm® and CLENZIDerm®.

Sell $190M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-21 Allegro Ophthalmics - Ophthalmology Assets

San Juan Capistrano, California, United States

Allegro Ophthalmics LLC - Ophthalmology Assets includes global rights for risuteganib (Luminate®)1, Allegro's lead investigational compound in the retina, which is believed to simultaneously act on the angiogenic, inflammatory, and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration (AMD).

Buy -

Seller(S) 1

SELLER

Synergy Pharmaceuticals

New York, New York, United States
Category Company
Sector Life Science
Employees291
Revenue 16M USD (2017)
DESCRIPTION

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel GI therapies. The company has pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Synergy’s proprietary GI platform includes one commercial product TRULANCE and a second lead product candidate, dolcanatide.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (New York) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal